Streetbeat News

Analyst Ratings

SATS

Raymond James analyst Ric Prentiss has maintained a Strong Buy rating on EchoStar (NASDAQ:SATS) but lowered the price target from $54 to $37.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:25 pm

DISH

Raymond James analyst Ric Prentiss has maintained a 'Strong Buy' rating on DISH Network (NASDAQ:DISH), but lowered the price target from $19 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:24 pm

AMRC

Raymond James analyst Pavel Molchanov has maintained an 'Outperform' rating on Ameresco (NYSE:AMRC), but lowered the price target from $55 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:22 pm

EVCM

Raymond James analyst Brian Peterson has maintained an Outperform rating on EverCommerce (NASDAQ:EVCM) but lowered the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:20 pm

PAY

Raymond James analyst John Davis maintains an 'Outperform' rating on Paymentus Holdings (NYSE:PAY) and raises the price target from $13 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:18 pm

RNG

Raymond James analyst Brian Peterson has maintained a 'Strong Buy' rating on RingCentral (NYSE:RNG) but lowered the price target from $60 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:17 pm

TGLS

Raymond James analyst Sam Darkatsh has maintained a Strong Buy rating on Tecnoglass (NYSE:TGLS), but lowered the price target from $52 to $45.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:15 pm

VVX

Raymond James analyst Brian Gesuale maintains a Strong Buy rating on V2X (NYSE:VVX) but has lowered the price target from $65 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:13 pm

CYTK

B. Riley Securities has initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:10 pm

VTYX

Morgan Stanley analyst Vikram Purohit has downgraded Ventyx Biosciences from Overweight to Equal-Weight and lowered the price target from $46 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 7:06 pm